TheraMe!
Why go for a standard care cancer therapy if there are no standardized cancers
Our vision
Shaping the future of cancer therapy by providing:
Up to 400+ therapy options being tested
By using mircofluidic technology, tiny biopsies are sufficient to perform more than a thousand tests to determine the best therapeutic option for each patient.
Targeted data analysis
We use propriety computational programs and machine learning to derive the best possible therapy for each patient, while applying strict quality control for all data sets obtained from microfluidic screens.
Affordable screening cost
Due to miniaturization, reagent costs are strongly reduced and we can offer patient screens at prices similar to those for standard diagnostic techniques (e.g. MRI scans).
Fast results
Within 24h for functional readout and 5 working days for transcriptomic readout. Hence, the most effective drug combinations are communicated to the doctors before the therapy starts and repetitive screens can be performed to monitor resistances and to determine effective second line alternatives.
Presenting
The MatchMe™ IVD device who makes personalized cancer therapy possible!
Our success
10
years of research
performed screens
We work together with hospitals in Germany and the USA. They provide us directly with cancer samples from consenting patients.
145+
highly skilled people
Highly skilled experts in microfluidic technology and personalized medicine. The strength of TheraMe! is its team’s multidisciplinary expertise.
9
Our partners
TheraMe! has gained the support of renowned partners.
In 2018, the potential of our technology for both clinical applicability and commercialization was recognized by the German Ministry of Economy and Energy, resulting in the award of an EXIST grant. In 2020, the host lab of TheraMe! was granted a prestigious Innosuisse grant by the Swiss Innovation Agency. Additionally, in 2021, the lab received significant funding through the PHRT strategic focus area of the ETH Domain. In April 2024, TheraMe! was awarded another Innosuisse grant for the development of an industrial prototype in collaboration with CSEM.
Furthermore, TheraMe! was selected as a finalist in the Venture competition, among 10 finalists in the Health & Nutrition in 2022. Moreover, TheraMe! won the audience award at the AGORA BioInnovation day in 2023.
